F8 and hemophilia: However, the evolution in therapy for hemophilia has been extraordinary, moving from plasma-derived to recombinant FVIII and FIX, and then from standard half-life (SHL) recombinant products to extended half-life (EHL) products to bypassing agents, FVIII mimetics, and even gene therapy.